ACM
MLTX icon

Atika Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Atika Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-85,000
Closed -$4.84M – 87
2023
Q3 		$4.84M Buy
+85,000
New +$4.69M 0.64% 54

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Atika Capital Management's MLTX Position: Q4 2023 in Review

Atika Capital Management sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2023, closing a stake of 85,000 shares — an estimated $4.84M sold.

Atika Capital Management first reported a position in MLTX in Q3 2023 and held it in 1 quarter. The position peaked at $4.84M in Q3 2023. 125 funds tracked by Wall St. Rank hold MLTX as of Q4 2023.

  • Atika Capital Management reported no remaining MoonLake Immunotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Atika Capital Management sold 85,000 MoonLake Immunotherapeutics shares in Q4 2023, an estimated $4.84M.
  • Atika Capital Management first reported a position in MoonLake Immunotherapeutics in Q3 2023 and held it in 1 quarter.
  • Atika Capital Management's MoonLake Immunotherapeutics position peaked at $4.84M in Q3 2023.
  • 125 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2023.

Based on Atika Capital Management's 13F filing for Q4 2023, filed 13 Feb 2024.